Vaxart Inc (NASDAQ: VXRT) closed the day trading at $1.29 up 1.97% from the previous closing price of $1.27. In other words, the price has increased by $+0.0250 from its previous closing price. On the day, 1269851 shares were traded.
Ratios:
For a better understanding of VXRT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.07 and its Current Ratio is at 5.07. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.32.
On November 02, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $15.
B. Riley Securities Downgraded its Buy to Neutral on June 29, 2021, whereas the target price for the stock was revised from $13 to $9.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VXRT now has a Market Capitalization of 199.43M and an Enterprise Value of 167.64M. For the stock, the TTM Price-to-Sale (P/S) ratio is 52.56 while its Price-to-Book (P/B) ratio in mrq is 2.75. Its current Enterprise Value per Revenue stands at 216.04 whereas that against EBITDA is -2.10.
Stock Price History:
Over the past 52 weeks, VXRT has reached a high of $1.59, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 0.8828, while the 200-Day Moving Average is calculated to be 0.8313.
Shares Statistics:
Over the past 3-months, VXRT traded about 1.73M shares per day on average, while over the past 10 days, VXRT traded about 2.13M shares per day. A total of 168.84M shares are outstanding, with a floating share count of 167.57M. Insiders hold about 0.75% of the company’s shares, while institutions hold 18.57% stake in the company. Shares short for VXRT as of Feb 15, 2024 were 12.67M with a Short Ratio of 7.32, compared to 11.48M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.26% and a Short% of Float of 8.31%.
Earnings Estimates
Current recommendations for the stock of the company come from 2 analysts. On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.16, while EPS last year was -$0.18. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.56 and -$0.66 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.49, with 2 analysts recommending between -$0.4 and -$0.58.
Revenue Estimates
2 analysts predict $1.25M in revenue for the current quarter. It ranges from a high estimate of $2.4M to a low estimate of $100k. As of the current estimate, Vaxart Inc’s year-ago sales were $22k, an estimated increase of 5,581.80% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.4M, an increase of 200.00% less than the figure of $5,581.80% in the same quarter last year. There is a high estimate of $2.4M for the next quarter, whereas the lowest estimate is $2.4M.
A total of 2 analysts have provided revenue estimates for VXRT’s current fiscal year. The highest revenue estimate was $4.2M, while the lowest revenue estimate was $2M, resulting in an average revenue estimate of $3.1M. In the same quarter a year ago, actual revenue was $107k, up 2,797.20% from the average estimate.
